decitabine
information and resources from the National Cancer Institute
decitabine
A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication.decitabine
A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication.
|
|
|
|
news articles
Maintenance Treatment with Decitabine Suggested for MDS Mar 14, 2006
Cancerpage.com, MAR 13, 2006 (Reuters Health) - In patients with myelodysplastic syndromes (MDS), relapse often follows a first successful course of treatment with decitabine. ...
Decitabine improves patient outcomes in myelodysplastic syndromes Mar 14, 2006
News-Medical.net, Decitabine, a new drug undergoing Phase III efficacy trials, provides palliative therapy for patients with the bone marrow disease called Myelodysplastic ...
Decitabine improves myelodysplastic syndrome treatment Mar 14, 2006
News-Medical.net, The drug, decitabine, is designed to turn on genes that cancer had switched off, and in this study, patients who were treated with it achieved a significantly ...
Longer Treatment With Dacogen (decitabine) Advised for Pre ... Mar 14, 2006
MedPage Today, FREIBURG, Germany, March 14 - Dacogen (decitabine) therapy for patients with myelodysplastic syndrome (MDS) should extend beyond the first response and should ...
Decitabine Improves Outcomes in Myelodysplastic Syndromes Mar 14, 2006
Cancer Consultants (press release), According to results from an early online publication in the journal Cancer, Dacogen™ (decitabine) improves outcomes compared with supportive care only in ...
Continued Treatment with Dacogen™ May Be Superior to Retreatment ... Mar 14, 2006
Cancer Consultants (press release), According to results published in an early online edition of the journal Cancer, retreatment with Dacogen™ (decitabine) upon disease progression provides ...
Supergen drug tested for MDS Mar 13, 2006
Monsters and Critics.com, WASHINGTON, DC, United States (UPI) -- SuperGen`s investigational drug decitabine increases disease-free responses in patients with myelodysplastic syndrome ...
New study recommends treatment change for pre-leukemia disease Mar 13, 2006
Pharmaceutical Business Review Led by Dr Michael Lubbert, of the University of Freiburg Medical Center in Freiburg, Germany, researchers assessed the efficacy of decitabine retreatment on ...
Longer Drug Therapy Helps Bone Marrow Disease Patients Mar 17, 2006
Forbes FRIDAY, March 17 (HealthDay News) -- Longer courses of treatment with decitabine -- a drug currently undergoing clinical trials -- may help patients with a ...
Study Recommends Treatment Change for Pre-Leukemia Disease Mar 13, 2006
Wiley InterScience, These high-risk patients have been shown to benefit from a new DNA hypomethylating agent, decitabine, undergoing clinical trials. ...
Analysis: Supergen drug tested for MDS Mar 13, 2006
United Press International WASHINGTON, March 13 (UPI) -- SuperGen's investigational drug decitabine increases disease-free responses in patients with myelodysplastic syndrome and could ...
Drug Eases Bone Marrow Cancer Burden Mar 13, 2006
Forbes However, decitabine -- currently undergoing Phase III efficacy trials -- may not extend the survival of patients with this disease, experts say. ...
New drug improves bone marrow cancer outlook Mar 14, 2006
Cancerfacts.com, The study led by Dr. Hagop Kantarjian, of the University of Texas MD Anderson Cancer Center in Houston, is testing the new drug, decitabine, in large ...
Dacogen™ Improves Outcomes in Myelodysplastic Syndromes Mar 15, 2006
Cancer Consultants (press release), A multicenter trial demonstrated that treatment with the hypomethylating agent Dacogen™ (decitabine) was superior to supportive care of poor risk patients ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Genetic Engineering News, ...has accepted the Companies' resubmission as of November 15, 2005 as a complete response to the Approvable Letter for Dacogen(TM) (decitabine) injection for ...
Dacogen(TM) (Decitabine) Injection Data Presented at American ... Dec 12, 2005
Genetic Engineering News, MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today provided a summary of the Dacogen(TM) (decitabine) injection presentations made during ...
Early Phase 1 Trial of Decitabine Suggests a Low Dose May Reduce ... Nov 18, 2005
DG News PHILADELPHIA, PA -- November 18, 2005 -- Low-dose decitabine is well tolerated in heavily pretreated patients with cancer, according to early research ...
Dacogen(TM) (Decitabine) Injection Data Presented at American ... Dec 12, 2005
PR Newswire (press release), ...(Nasdaq: MOGN) and SuperGen, Inc. (Nasdaq: SUPG) today provided a summary of the Dacogen(TM) (decitabine) injection presentations made during the American ...
(PRN) - Vern Clark Elected to Raytheon Board of Directors ... [+] Dec 15, 2005
Bolsamania.com, 2005 Results ... [+. PRN) - Dacogen(TM) (Decitabine) Injection Complete Response Accepted for Review by US FDA ... [+. PRN) - PGP ...
BMS' dasatinib expected to rival Gleevec Nov 21, 2005
Science Daily (press release) Both are in preclinical development. Another medication that could factor into the CML market in 2006 is Supergen/MGI Pharma's decitabine. ...
Source: Quest Diagnostics Incorporated Dec 9, 2005
Yahoo! News (press release) Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.
(PRN) - Christopher & Banks Corporation Announces Resignation of ... Dec 12, 2005
Bolsamania.com, Solutions ... [+. PRN) - Dacogen(TM) (Decitabine) Injection Data Presented at American Society of Hematology (ASH) Annual Meeting ... [+. ...
|
|
